Should I Buy SCNI? SCNI 2026 Analysis

Should You Buy Scinai Immunotherapeutics Ltd (SCNI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.950

1 Day change

-1.96%

52 Week Range

6.180

Analysis Updated At

2026/01/30

SCNI is not a good buy right now for an impatient investor. There are no proprietary buy signals, no recent news-driven catalyst, weak/early-stage financials with continuing losses, and the short-term pattern probability skews negative over the next week. This setup is better avoided until a clearer breakout above resistance (around 1.08–1.16) or a fundamental catalyst appears.

Technical Analysis

Trend/price context: SCNI is trading around 0.99 (-1.97% regular session; +3.09% pre-market), near the pivot level at 0.951, indicating a largely range-bound, indecisive area rather than a clean trend. Momentum: MACD histogram is positive (0.0216) but 'positively contracting,' which often implies bullish momentum is fading rather than accelerating. RSI: RSI(6) ~49.5 (neutral), offering no strong overbought/oversold edge. Moving averages: Converging MAs suggest consolidation and lack of directional conviction. Levels: Support at ~0.821 (S1) then ~0.741 (S2). Resistance at ~1.081 (R1) then ~1.161 (R2). A durable move above 1.081 would improve the technical picture; failure risks a drop back toward 0.82. Pattern-based forward view: Similar-pattern stats imply a higher likelihood of weakness in the near term (approx. -3.76% next week) despite modest 1-month expectation (+0.66%). Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Positive Catalysts

- Pre-market strength (+3.09%) suggests some near-term buying interest.
- Price is above the pivot (0.951), so a quick breakout attempt toward 1.08 is possible if buyers step in.
- No notable negative insider/hedge fund trend signals reported (both neutral).

Neutral/Negative Catalysts

- No news in the last week: no clear event-driven catalyst to re-rate the stock.
- Momentum is not convincingly bullish (MACD contracting; RSI neutral; MAs converging).
- Pattern-based outlook leans negative over the next week.
- Micro-cap/low-price behavior implied by sub-$1 price level tends to amplify downside on failed breakouts.
- No congress trading data and no reported influential-figure activity to support sentiment.

Financial Performance

Latest quarter: 2024/Q4. Revenue was about $206K (flat YoY), while net income remained deeply negative at about -$2.23M (down ~4.29% YoY, i.e., loss widened). EPS fell to 0 (down 100% YoY in the snapshot). Gross margin is negative (around -164%), consistent with an early-stage/uneconomic operating profile. Overall: no clear growth inflection; losses persist, which reduces the attractiveness of buying without a strong technical or catalyst-driven trigger.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no observable recent Wall Street trend to lean on. Pros (typical bull case): optionality if pipeline/clinical progress emerges. Cons (typical bear case): limited revenue scale, ongoing losses, and lack of near-term catalysts—making timing-dependent trades less favorable without confirmed technical strength.

Analyst Rating

Wall Street analysts forecast SCNI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCNI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold